Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis
- PMID: 3330785
Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis
Abstract
We have examined the genomic organisation of c-myc, N-myc, L-myc, neu and N-ras in tissue from 41 breast carcinomas, lymph node metastases from 10 of these carcinomas, one fibrosarcoma, 10 cases of benign fibrocystic breast and six fibroadenomas. We have not observed an alteration in either N-myc or N-ras in any of the samples studied. We have seen a 2-fold amplification of L=myc in DNA from one infiltrating ductal (ID) carcinoma, but otherwise we have seen no alterations to this gene. Amplification of c-myc was seen in 22% of ID breast carcinoma sample. Levels of amplification ranged from 2- to 10-fold. We have found a significant (p less than 0.02) correlation between an altered c-myc gene and a very poor short-term prognosis. Amplification of neu was seen in 19% of ID breast carcinomas, but the levels of amplification were higher than those seen for c-myc. Alterations to neu also correlated well with poor short-term prognosis (p less than 0.0002). Finally, we have observed a low level of amplification of c-myc in DNA from a benign fibrocystic breast lesion. This lesion exhibited some features characteristic of those thought to be associated with an increased risk of developing breast cancer.
Similar articles
-
Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis.Oncogene Res. 1988;3(1):21-31. Oncogene Res. 1988. PMID: 2905033
-
Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas.Cancer Res. 1989 Dec 1;49(23):6675-9. Cancer Res. 1989. PMID: 2573420
-
Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.Cancer Res. 1991 Jan 15;51(2):556-67. Cancer Res. 1991. PMID: 1670762
-
The human breast carcinoma cell line SW 613-S: an experimental system to study tumor heterogeneity in relation to c-myc amplification, growth factor production and other markers (review).Anticancer Res. 1989 Sep-Oct;9(5):1265-79. Anticancer Res. 1989. PMID: 2686529 Review.
-
Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene.Pathol Annu. 1992;27 Pt 1:165-90. Pathol Annu. 1992. PMID: 1346551 Review.
Cited by
-
The long term prognostic significance of c-erbB-2 in primary breast cancer.Br J Cancer. 1991 Mar;63(3):447-50. doi: 10.1038/bjc.1991.103. Br J Cancer. 1991. PMID: 1672256 Free PMC article.
-
c-erbB-2 expression in different histological types of invasive breast carcinoma.J Clin Pathol. 1991 Mar;44(3):211-4. doi: 10.1136/jcp.44.3.211. J Clin Pathol. 1991. PMID: 1672872 Free PMC article.
-
Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.Breast Cancer Res Treat. 1991 Dec;20(1):3-10. doi: 10.1007/BF01833351. Breast Cancer Res Treat. 1991. PMID: 1687505
-
Breast cancer and a proto-oncogene.BMJ. 1989 Oct 28;299(6707):1061-2. doi: 10.1136/bmj.299.6707.1061. BMJ. 1989. PMID: 2511965 Free PMC article. Review. No abstract available.
-
Genomic alterations of primary tumor and blood in invasive ductal carcinoma of breast.World J Surg Oncol. 2010 Apr 21;8:32. doi: 10.1186/1477-7819-8-32. World J Surg Oncol. 2010. PMID: 20409316 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous